SARS-CoV-2 Vaccination and Hidradenitis Suppurativa: Role of Vaccination in Disease Activity

A retrospective study of 222 patients with hidradenitis suppurativa (HS) found that 9.5% experienced flares within 2 weeks of SARS-CoV-2 vaccination, with a mean onset of 8.9 days. Flares were more common in patients with higher Hurley stages, particularly Stage III, and biologic treatment was linked to a lower risk of flares. A larger multicenter study involving 1,279,188 vaccinated individuals, including 3,418 HS patients, found no significant difference in flare risk between vaccinated and unvaccinated groups. The study concludes that SARS-CoV-2 vaccines are generally safe for HS patients, but further research is needed due to the retrospective nature and lack of a control group.